Prognostic Value of Tumor Budding in Early-Stage Cervical Adenocarcinomas

Nopporn Satabongkoch¹, Surapan Khunamornpong¹*, Tip Pongsuvareeyakul¹, Jongsin Seetakorn¹, Kornkanok Sukpan¹, Aungsumalee Soongkhaw², Suthida intaraphet³, Prapaporn Suprasert⁴, Sumalee Siriaunkgul¹

Abstract

Background: Tumor budding has recently been reported as an independent adverse prognostic factor for colorectal adenocarcinomas and other types of carcinoma in the digestive tract. This study aimed to evaluate the prognostic value of tumor budding in patients with early-stage cervical adenocarcinomas and any associations with other clinical and pathological features.

Methods: Histological slides of patients with early-stage (IB-IIA) usual-type endocervical adenocarcinoma who underwent radical hysterectomy and pelvic lymph node dissection, without preoperative chemotherapy, between January 2006 and December 2012 were reviewed. Tumor budding was evaluated in routinely-stained sections and defined as detached single cells or clusters of fewer than 5 cells in a tumor invasive front and was stratified based on the number of bud counts in 10-high-power fields as low (<15 buds) and high (≥15 buds). Correlations between tumor bud count and other clinical and pathological variables including follow-up outcomes were assessed.

Results: Of 129 patients, a high tumor bud count was observed in 15 (11.6%), positively associated with histologic grade 3 (p<0.001), invasive pattern C (Silva System) (p=0.004), lymph node metastasis (p=0.008), stage IB-IIA (p=0.016), and tumor size >2 cm (p=0.036). Kaplan-Meier analysis showed a significant decrease in both disease-free survival and cancer-specific survival for patients with a high tumor bud count (p=0.027 and 0.031, respectively). On multivariate analysis, histologic grade 3 was the only independent predictor for decreased disease-free survival (p=0.004) and cancer-specific survival (p=0.003).

Conclusions: A high tumor budding count based on assessment of routinely-stained sections was found to be associated with decreased disease-free and cancer-specific survival in patients with early-stage cervical adenocarcinomas. However, it was not found to be an independent prognostic predictor in this study.

Keywords: Uterine cervix- adenocarcinoma- tumor budding- prognosis

Asian Pac J Cancer Prev, 18 (6), 1717-1722

Introduction

Cervical cancer is the third most common cancer in women worldwide, and is the second leading cause of cancer death in women of developing countries (Torre et al., 2015). In Thailand, cervical cancer is the second most common cancer with an average age-standardized rate of 14.4 per 100,000 women (Wilailak and Lertchaipattanakul, 2016).

Squamous cell carcinoma is the predominant histological type of cervical cancer, accounting for approximately 80% of cases (Wilailak and Lertchaipattanakul, 2016). Although adenocarcinoma is a less common histologic type, its incidence has been increasing up to 20-25% during the last two decades in the Western women population (Roma et al., 2015). In general, clinicopathological prognostic factors in patients with cervical carcinoma include patient’s age, the International Federation of Gynecology and Obstetrics (FIGO) tumor stage, tumor size, histologic type and grade, lymphovascular space invasion (LVSI), depth of cervical wall invasion, parametrial involvement, lymph node metastasis, and treatment modality (Bieval et al., 2011; Intaraphet et al., 2013). The prognosis of patients with adenocarcinoma may be worse than those with squamous cell carcinoma even in early-stage patients (Intaraphet et al., 2013). In addition to tumor stage, histologic grade, and lymph node metastasis (Bieval et al., 2004), the prognostic variables that determine an appropriate management and disease outcome in patients with early-stage cervical adenocarcinoma remain to be determined.

Tumor budding has recently been a well-established independent adverse prognostic factor in colorectal adenocarcinoma (Karamitopoulou et al., 2013).
High-grade (or high number) of tumor budding is associated with lymph node metastasis, local recurrence, distant metastasis, and worsened disease-free and overall survival (Zlobec and Lugli, 2010). The prognostic value of tumor budding has been reported in patients with all stages of colorectal adenocarcinoma, and tumor budding may be used for risk stratification of patients, for justification of adjuvant chemotherapy, and probably for prediction of response to targeted therapy (Mitrovic et al., 2012). Tumor budding has also been found to be an independent prognostic variable in other types of carcinoma in the digestive system, including the esophagus (Teramoto et al., 2013; Landau et al., 2014), stomach (Gulluoglu et al., 2015), ampulla (Ohike et al., 2010), and pancreas (Karamitopoulou, 2013; O’Connor et al., 2015).

To our knowledge, the evaluation of tumor budding and its clinical significance in cervical adenocarcinoma has not been reported. This study was aimed to evaluate the prognostic value of tumor budding in patients with early-stage cervical adenocarcinoma and the association of tumor budding with other clinical and pathological features.

**Material and Methods**

This study was approved by the Institutional Research Ethics Board. The surgical pathology records of the Department of Pathology, Faculty of Medicine, Chiang Mai University, were searched for the cases of cervical adenocarcinoma who underwent radical hysterectomy and pelvic lymph node dissection between January 2006 and December 2012. The cases diagnosed between 2006 and 2011 had been included as a part of our previous study of cervical adenocarcinoma without the assessment of tumor budding (Pongsuvareeyakul et al., 2015). Data of the medical records of the identified cases were retrieved. The inclusion criteria were: surgery performed in Chiang Mai University Hospital; histology of endocervical adenocarcinoma of usual type; and FIGO stage IB to IIA. The exclusion criteria were: adenosquamous carcinoma or non-usual types of cervical adenocarcinoma (Wibur et al., 2013); patients who received preoperative chemotherapy or radiation therapy due to the presence of any high-risk pathological features (positive lymph nodes, surgical margins, or parametrial involvement) or a combination of at least 2 intermediate-risk pathological features (deep stromal invasion, extensive LVI, or tumor size >4 cm).

For the assessment of interobserver agreement, another pathologist (S.K.) evaluated the selected slides and scored the invasive pattern (pattern C versus pattern A or B) and the tumor bud count (high versus low). In the cases with disagreement of the results, a third pathologist (K.S.) evaluated the slides. The final results of invasive pattern and tumor budding used in the study were based on the agreement of at least 2 pathologists.

Clinical information including patient age, treatment modalities and clinical follow-up outcomes or cause of death was retrieved from medical records or data obtained from the cancer registry. Regarding adjuvant treatment, the patients were justified for adjuvant chemotherapy and/or radiation therapy due to the presence of any high-risk pathological features (positive lymph nodes, surgical margins, or parametrial involvement) or a combination of at least 2 intermediate-risk pathological features (deep stromal invasion, extensive LVI, or tumor size >4 cm).

The data were analyzed using STATA version 11 (StataCorp LP, College Station, TX, USA). The interobserver agreement between pathologists (N.S.
and S.K.) was assessed using the Kappa statistic. The associations of tumor bud count and other clinical and pathological variables were assessed using the Fisher’s exact test. The Kaplan-Meier method and log-rank test were used for analysis and comparison of survival curves. Cox regression models were used to perform univariate and multivariate analyses of disease-free survival and cancer-specific survival. The variables with a p value of less than 0.25 in the univariate analysis were further evaluated in the multivariate analysis. A p value of less than 0.05 was considered statistically significant.

Disease-free survival was defined as the time period between the date of surgery until disease recurrence (locoregional or distant), the last follow-up, or censoring. Cancer-specific survival was defined as the time period between the date of surgery until death from cancer, the last follow-up, or censoring.

**Results**

A total of 129 patients were included into the study. The mean age was 45.4±9.4 years. The FIGO stage was IB1 in 89 patients (69.0%), IB2 in 28 patients (21.7%), and IIA in 12 patients (9.3%). Lymph node metastasis was detected in 24 patients (18.6%). The follow-up duration ranged from 2 to 120 months (median 60 months). Twenty-three patients (17.8%) were known to have tumor recurrence, and 18 (14.0%) had cancer-related death.

The invasive pattern A was observed in 18 patients (16.0%), pattern B in 39 patients (29.8%), and invasive pattern C in 71 patients (54.2%). Lymph node metastasis was present in none of patients with invasive pattern A (0%), 3 of 36 (8.3%) of patients with pattern B, and 21 of 75 (27.6%) patients with pattern C. The difference in the rates of lymph node metastasis was significant between pattern C and pattern B (p=0.015), and between pattern C and pattern A (p=0.010), but not between pattern B and pattern A (p=0.543). The agreement of invasive pattern scoring between both pathologists was observed in 102 cases (79.1%). The Kappa statistic was 0.56, consistent with moderate agreement.

The number of tumor bud count ranged from 0 to 35 in 10 HPF (median 2). A high tumor bud count was observed in 15 patients (11.6%), and a low bud count in 114 patients (88.4%). The agreement of tumor bud count (high versus low) was observed in 110 cases (85.3%), with Kappa statistic of 0.30 which indicated fair agreement.

The association of tumor budding with other clinical and pathological features is shown in Table 1. A high tumor bud count was significantly associated with histologic grade 3 (p<0.001), invasive pattern C, lymph node metastasis, stage IB2-IIA, and tumor size >2 cm. In comparison with the patients who had a low tumor bud count, those with a high bud count had higher

| Variable                      | No. of patients (%) | Tumor budding count | p value |
|-------------------------------|---------------------|---------------------|---------|
| Low number (%)                | n=114               | High number (%)     | n=15    |         |
| Age                           |                     |                     |         |
| ≤45 years                     | 71 (55.0)           | 61 (53.5)           | 10 (66.7) | 0.414   |
| >45 years                     | 58 (45.0)           | 53 (46.5)           | 5 (33.3)  |         |
| Stage                         |                     |                     |         |
| IB1                           | 89 (69.0)           | 83 (72.8)           | 6 (40.0)  | 0.016   |
| IB2-IIA                       | 40 (31.0)           | 31 (27.2)           | 9 (60.0)  |         |
| Tumor size                    |                     |                     |         |
| ≤2.0 cm                       | 42 (32.6)           | 41 (36.0)           | 1 (6.7)   | 0.036   |
| >2.0 cm                       | 87 (67.4)           | 73 (64.0)           | 14 (93.3) |         |
| Histologic grade              |                     |                     |         |
| Grade 1-2                     | 113 (87.6)          | 105 (92.1)          | 8 (53.3)  | <0.001  |
| Grade 3                       | 16 (12.4)           | 9 (7.9)             | 7 (46.7)  |         |
| Pattern of invasion           |                     |                     |         |
| Patterns A and B              | 54 (41.9)           | 53 (46.5)           | 1 (6.7)   | 0.004   |
| Pattern C                     | 75 (58.1)           | 61 (53.5)           | 14 (93.3) |         |
| Depth of invasion             |                     |                     |         |
| Inner or middle third         | 54 (41.9)           | 48 (42.1)           | 6 (40.0)  | >0.99   |
| Outer third                   | 75 (58.1)           | 66 (57.9)           | 9 (60.0)  |         |
| Residual stroma               |                     |                     |         |
| <3mm                          | 78 (60.5)           | 72 (63.2)           | 6 (40.0)  | 0.098   |
| Yes                           | 51 (39.5)           | 42 (36.8)           | 9 (60.0)  |         |
| Lymphovascular space invasion |                     |                     |         |
| No                            | 56 (43.4)           | 53 (46.5)           | 3 (20.0)  | 0.058   |
| Yes                           | 73 (56.6)           | 61 (53.5)           | 12 (80.0) |         |
| Parametrial involvement       |                     |                     |         |
| No                            | 107 (82.9)          | 95 (83.3)           | 12 (80.0) | 0.720   |
| Yes                           | 22 (17.1)           | 19 (16.7)           | 3 (20.0)  |         |
| Vaginal margin involvement    |                     |                     |         |
| No                            | 124 (96.1)          | 110 (96.5)          | 14 (93.3) | 0.467   |
| Yes                           | 5 (3.9)             | 4 (3.5)             | 1 (6.7)   |         |
| Lymph node metastasis         |                     |                     |         |
| No                            | 105 (81.4)          | 97 (85.1)           | 8 (53.3)  | 0.008   |
| Yes                           | 24 (18.6)           | 17 (14.9)           | 7 (46.7)  |         |

Table 1. Association of Tumor Budding and Clinical and Pathological Variables in 129 Patients
proportions of LVSI and residual stroma <3 mm, but the differences were not statistically significant. The presence of extensive LVSI was not significantly associated with a high tumor bud count (40.0% in high count vs 26.3% in low count, p=0.357). There was a marginal difference in the proportion of patients who received adjuvant therapy between the groups with high and low tumor bud counts (66.7% vs 41.2%, p=0.095).

The patients with a high tumor bud count had significantly higher rates of recurrence and cancer-specific death than those with a low bud count (recurrence: 40.0% vs 14.9%, p=0.033; death: 33.3% vs 11.4%, p=0.037). The Kaplan-Meier analysis showed a significant association of high tumor bud count with decreased disease-free survival.

### Table 2. Univariate and Multivariate Analysis of Clinical and Pathological Variables on Disease-Free Survival

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | p value               | HR (95% CI)         | p value               |
| Age                             |                     |                       |                      |
| ≤45 years                       | Reference           | 0.448                 | -                     |
| >45 years                       | 1.4 (0.6-3.1)       | -                     |
| Stage                           |                     |                       |                      |
| IB1                             | Reference           | 0.009                 | Reference           | 0.738                 |
| IB2-IIA                         | 3.0 (1.3-6.8)       | 1.3 (0.3-4.8)         |                       |
| Tumor bud count                 |                     |                       |                      |
| Low number                      | Reference           | 0.035                 | Reference           | 0.937                 |
| High number                     | 2.7 (1.1-6.9)       | 1.1 (0.3-3.7)         |                       |
| Tumor size                      |                     |                       |                      |
| ≤2.0 cm                         | Reference           | 0.025                 | Reference           | 0.139                 |
| >2.0 cm                         | 5.3 (1.2-22.4)      | 3.8 (0.6-23.2)        |                       |
| Histologic grade                |                     |                       |                      |
| Grade 1-2                       | Reference           | 0.001                 | Reference           | 0.004                 |
| Grade 3                         | 2.1 (1.3-3.2)       | 2.5 (1.3-4.5)         |                       |
| Pattern of invasion             |                     |                       |                      |
| Patterns A and B                | Reference           | 0.140                 | Reference           | 0.056                 |
| Pattern C                       | 2.0 (0.8-5.1)       | 0.3 (0.1-1.0)         |                       |
| Depth of invasion               |                     |                       |                      |
| Inner or middle third           | Reference           | 0.019                 | Reference           | 0.181                 |
| Outer third                     | 3.6 (1.2-10.7)      | 2.8 (0.6-12.4)        |                       |
| Residual stroma <3 mm           |                     |                       |                      |
| No                              | Reference           | 0.084                 | Reference           | 0.499                 |
| Yes                             | 2.1 (0.9-4.7)       | 0.7 (0.2-2.2)         |                       |
| Lymphovascular space invasion   |                     |                       |                      |
| No                              | Reference           | 0.006                 | Reference           | 0.123                 |
| Yes                             | 5.5 (1.6-18.4)      | 2.9 (0.7-11.9)        |                       |
| Parametrial involvement         |                     |                       |                      |
| No                              | Reference           | 0.013                 | Reference           | 0.722                 |
| Yes                             | 3.0 (1.3-7.1)       | 1.3 (0.4-4.4)         |                       |
| Vaginal margin involvement      |                     |                       |                      |
| No                              | Reference           | 0.971                 | -                     |
| Yes                             | 1.0 (0.1-7.2)       | -                     | -                     |
| Lymph node metastasis           |                     |                       |                      |
| No                              | Reference           | 0.001                 | Reference           | 0.088                 |
| Yes                             | 4.1 (1.8-9.3)       | 2.8 (0.9-9.4)         |                       |
| Adjuvant therapy                |                     |                       |                      |
| No                              | Reference           | 0.002                 | Reference           | 0.936                 |
| Yes                             | 4.7 (1.7-12.7)      | 1.1 (0.3-4.1)         |                       |

### Table 3. Univariate and Multivariate Analysis of Clinical and Pathological Variables on Cancer-Specific survival

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | p value               | HR (95% CI)         | p value               |
| Age                             |                     |                       |                      |
| ≤45 years                       | Reference           | 0.98                  | -                     |
| >45 years                       | 1.0 (0.4-2.5)       | -                     |
| Stage                           |                     |                       |                      |
| IB1                             | Reference           | 0.077                 | Reference           | 0.981                 |
| IB2-IIA                         | 2.3 (0.9-5.8)       | 1.0 (0.2-4.6)         |                       |
| Tumor bud count                 |                     |                       |                      |
| Low number                      | Reference           | 0.040                 | Reference           | 0.910                 |
| High number                     | 3.0 (1.1-8.3)       | 1.1 (0.3-4.1)         |                       |
| Tumor size                      |                     |                       |                      |
| ≤2.0 cm                         | Reference           | 0.071                 | Reference           | 0.132                 |
| >2.0 cm                         | 3.9 (0.9-16.9)      | 4.1 (0.7-26.1)        |                       |
| Histologic grade                |                     |                       |                      |
| Grade 1-2                       | Reference           | 0.001                 | Reference           | 0.003                 |
| Grade 3                         | 2.2 (1.4-3.6)       | 2.7 (1.4-5.2)         |                       |
| Pattern of invasion             |                     |                       |                      |
| Patterns A and B                | Reference           | 0.225                 | Reference           | 0.108                 |
| Pattern C                       | 1.9 (0.7-5.3)       | 0.3 (0.1-1.3)         |                       |
| Depth of invasion               |                     |                       |                      |
| Inner or middle third           | Reference           | 0.104                 | Reference           | 0.462                 |
| Outer third                     | 2.5 (0.8-7.6)       | 1.8 (0.4-9.2)         |                       |
| Residual stroma <3 mm           |                     |                       |                      |
| No                              | Reference           | 0.156                 | Reference           | 0.769                 |
| Yes                             | 2.0 (0.8-5.0)       | 0.8 (0.2-3.4)         |                       |
| Lymphovascular space invasion   |                     |                       |                      |
| No                              | Reference           | 0.013                 | Reference           | 0.090                 |
| Yes                             | 6.4 (1.5-27.8)      | 4.2 (0.9-21.9)        |                       |
| Parametrial involvement         |                     |                       |                      |
| No                              | Reference           | 0.042                 | Reference           | 0.824                 |
| Yes                             | 2.8 (1.0-7.4)       | 1.2 (0.3-5.5)         |                       |
| Vaginal margin involvement      |                     |                       |                      |
| No                              | Reference           | 0.784                 | -                     |
| Yes                             | 1.3 (1.2-10.0)      | -                     | -                     |
| Lymph node metastasis           |                     |                       |                      |
| No                              | Reference           | 0.003                 | Reference           | 0.158                 |
| Yes                             | 4.1 (1.6-10.4)      | 2.8 (0.8-11.7)        |                       |
| Adjuvant therapy                |                     |                       |                      |
| No                              | Reference           | 0.027                 | Reference           | 0.651                 |
| Yes                             | 3.2 (1.1-9.0)       | 0.7 (0.2-3.2)         |                       |

HR, hazard ratio; CI, confidence interval
Tumor Budding in Cervical Adenocarcinoma

Although the prognostic value of tumor budding has been extensively studied in colorectal cancer, the methodologies and scoring systems for “high-grade” tumor budding are not always uniform across the studies (Mitrovic et al., 2012; Horcic et al., 2013). The counting method using 10 HPF area in the present study was based on the recent proposal for the assessment of tumor budding in colorectal cancer (Karamitopoulou et al., 2013). High-grade tumor budding as classified using an average bud count ≥10 per HPF was found to have an independent prognostic value (Horcic et al., 2013; Karamitopoulou et al., 2013). However, cervical adenocarcinoma in the present study had a much lower number of tumor budding than colorectal cancer as none of the 129 patients had an average bud count reaching 10 per HPF.

In this study, high tumor bud count in early-stage cervical adenocarcinoma, as defined by ≥15 buds in 10 HPF of routinely-stained histologic sections, was associated with the well-recognized adverse prognostic features, particularly histologic grade 3 and lymph node metastasis, as well as the recently described invasive pattern C (Baalbergen et al., 2004; Roma et al., 2015).

Tumor budding was significantly associated with worsened disease-free and cancer-specific survival, although it was not found to be an independent prognostic predictor on multivariate analysis. The assessment for interobserver variability showed only fair agreement on tumor bud count based on the examination of routinely-stained slides. The finding indicates that immunohistochemical stain for cytokeratin may be necessary for a more reliable evaluation of tumor budding in cervical adenocarcinoma (Mitrovic et al., 2012).

The recently proposed pattern-based classification system for cervical adenocarcinoma of usual type has shown a better performance in predicting lymph node metastasis than the measurement of invasive extent (Diaz De Vivar et al., 2013). The risk for lymph node metastasis was different between the 3 invasive patterns: pattern A (risk 0%), pattern B (risk 4.4%), and pattern C (risk 23.8%) (Diaz De Vivar et al., 2013). In this study, the case proportion of each invasive pattern and the rate of lymph node metastasis in each pattern were in keeping with the previously reported findings. However, the invasive pattern C was not found to be an adverse prognostic predictor on multivariate analysis. The invasive pattern C even showed some protective effect with hazard ratios of 0.3 for both disease-free survival and cancer-specific survival. Although the explanation for this finding is unclear, it may be possible that the adverse prognostic impact of invasive pattern C is driven by other prognostic variables that it is associated with. The moderate agreement between both pathologists in the diagnosis of invasive pattern in this study is in keeping with the recently reported finding, which suggests that further refinement of the diagnostic criteria may be needed (Rutgers et al., 2016).

This study had several limitations. We did not evaluate the predictive performance of the other methods for tumor bud counting and scoring systems which have been used in previous studies on colorectal and other types of cancers (Ohike et al., 2010; Horcic et al., 2013;...
Teramoto et al., 2013; Landau et al., 2014). Further studies may be necessary to clarify whether the other scoring methods could improve the prognostic significance of tumor budding in patients with cervical adenocarcinoma. Cytokeratin immunohistochemistry was not used in the assessment of tumor budding in this study. This immunostain may help to highlight the presence of cancer cells in the stroma and to reduce a misinterpretation of reactive non-epithelial cells as cancer cells, leading to a more accurate detection of tumor buds. A previous study has shown that interobserver agreement on the grading of tumor budding was improved from fair agreement using routinely-stained sections to substantial or almost perfect agreement using cytokeratin immunostaining (O’Connor et al., 2015). It should also be noted that in the present study, several well-recognized prognostic factors in cervical cancer patients were not found to have significant prognostic impact. It is possible that the fine selection of patients for adjuvant therapy based on the levels of risk variables may be related to the loss of prognostic significance of the risk factors in this study.

In conclusion, a high count of tumor budding based on the assessment of routinely-stained sections was associated with decreased disease-free and cancer-specific survivals in the patients with early-stage cervical adenocarcinoma. However, it was not found to be an independent prognostic predictor in this study.

Acknowledgement

This study was supported by 1) the National Research University Project, under Thailand’s Office of the Higher Education Commission; and 2) the Faculty of Medicine, Chiang Mai University. The authors declare that there is no conflict of interest.

References

Baalbergen A, Ewing-Graham PC, Hop WC, et al (2004). Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol, 92, 262-7.
Biewenga P, van der Velden J, Mol BW, et al (2011). Prognostic model for survival in patients with early stage cervical cancer. Cancer, 117, 768-76.
Diaz De Vivar A, Roma AA, Park KJ, et al (2013). Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol, 32, 592-601.
Gulluoglu M, Yegen G, Ozluk Y, et al (2015). Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int J Surg Pathol, 23, 349-58.
Horcic M, Koelzer VH, Karamitopoulou E, et al (2013). Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol, 44, 697-705.
Horn LC, Hentschel B, Braunmann UD (2008). Malignancy grading, pattern of invasion, and juxtatumoral stromal response (desmoplastic change) in squamous cell carcinoma of the uterine cervix. Int J Gynecol Pathol, 27, 606-7.
Intaraphet S, Kasatpibal N, Siriaunkgul S, et al (2013). Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. Asian Pac J Cancer Prev, 14, 5355-60.
Karamitopoulou E (2013). Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link?! Front Oncol, 3, 221.
Karamitopoulou E, Zlobec I, Kolzer V, et al (2013). Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol, 26, 295-301.
Khunamornpong S, Lekawanvijit S, Settakorn J, et al (2013). Prognostic model in patients with early-stage squamous cell carcinoma of the uterine cervix: a combination of invasive margin pathological characteristics and lymphovascular space invasion. Asian Pac J Cancer Prev, 14, 6935-40.
Landau MS, Hastings SM, Foxwell TJ, et al (2014). Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma. Mod Pathol, 27, 1578-89.
Mitrovic B, Schaeffer DF, Riddell RH, et al (2012). Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol, 25, 1315-25.
O’Connor K, Li-Chang HH, Kaloger SE, et al (2015). Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol, 39, 472-8.
Ohike N, Coban I, Kim GE, et al (2010). Tumor budding as a strong prognostic indicator in invasive amillary adenocarcinomas. Am J Surg Pathol, 34, 1417-24.
Pongsuvareycakul T, Khunamornpong S, Settakorn J, et al (2015). Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Asian Pac J Cancer Prev, 16, 4363-8.
Roma AA, Diaz De Vivar A, Park KJ, et al (2015). Invasive endocervical adenocarcinoma: A new pattern-based classification system with important clinical significance. Am J Surg Pathol, 39, 667-72.
Rutgers JK, Roma AA, Park KJ, et al (2016). Pattern classification of endocervical adenocarcinoma: reproducibility and review of criteria. Mod Pathol, 29, 1083-94.
Teramoto H, Koike M, Tanaka C, et al (2013). Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J Surg Oncol, 108, 42-6.
Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108.
Wibur DC, Colgan TJ, Ferenczy AS, et al (2014). Tumors of the uterine cervix. Glandular tumors and precursors. In ‘WHO classification of tumors of female reproductive organs’, Eds Kurman RJ, Carcangi ML., Harrington CS, Young RH. WHO press, Geneva, pp 183-9.
Wilailak S, Lerchaipattanakul N (2016). The epidemiologic status of gynecologic cancer in Thailand. J Gynecol Oncol, 27, e65.
Zlobec I, Lugli A (2010). Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget, 1, 651-61.